M.Sc. in biotechnology (Diplôme d'Ingénieur), University of Aix-Marseille, France (2009)
B.Sc. in life sciences, Pierre and Marie Curie–Paris VI University, France (2006)
Decision Resources Group, Director, Oncology (2016-present)
Decision Resources Group, Analyst, Oncology (2010-2016)
GlaxoSmithKline, Bench Scientist, Neurosciences (2009-2010)
Cancer, immuno-oncology, drug development, real-world data
Honors & Awards
Nawaz K and Webster RM. The bladder cancer drug market. Nat Rev Drug Discov. 2016 Sep;15(9):599-600.
Nawaz K and Webster RM. The non-small-cell lung cancer drug market. Nat Rev Drug Discov. 2016 Apr;15(4):229-30.
Immuno-Oncology: Global Market Forecast and U.S. Real World Data Trends for Immune Checkpoint Inhibitors
Immuno-oncology has reinvigorated the entire oncology field and transformed the management of a wide range of cancers. Most notably, immune checkpoint inhibitors and CAR T-cell therapies are at the forefront of this clinical revolution. Decision Resources Group keeps a finger on the pulse of the immuno-oncology landscape by blending market research data, comprehensive real-world data capabilities, and in-house oncology expertise. Drawing on our rich array of information, data, and insights, this presentation covers key commercial trends affecting the global market for immune checkpoint inhibitors, and puts the spotlight on U.S. claims data to uncover shifting dynamics in their uptake in the United States. We also touch on the clinical and commercial potential for CAR T-cell therapies.